A Phase 2 interventional study of APG-157 and Bevacizumab in recurrent high-grade glioma

Recruiting Phase 1,Phase 2 NCT06011109

Study Description

Evaluating the effectiveness of a new drug, APG-157, in combination with Bevacizumab for the treatment of recurrent high-grade brain tumors

Study Details

Registry ID:: NCT06011109
Conditions:: Glioma, Glioblastoma Multiforme
Phase:: Phase 1,Phase 2
Target Enrollment:: 30 participants
Start Date:: December 13, 2023
Age Range:: 19–999 years
Healthy Volunteers:: No

Study Locations (2 sites)

Mayo Clinic
Rochester, MinnesotaUnited States, United States
University of Nebraska Medical Center
Omaha, NebraskaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →